^
Association details:
| Biomarker: | TBX21 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | R-CHOP (cyclophosphamide + doxorubicin hydrochloride + + Rituxan (rituximab) + vincristine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
095 | Highly MultiplexTissue Imaging of DLBCL Identifies Novel Pathological Features Predictive of Overall Survival
Published date:
06/09/2021
Excerpt:
...to evaluate the prognostic significance of immune markers in R-CHOP treated DLBCL....Tumor expression of other markers including BCL2 (HR = 1.3; p < 0.05), phospho-histone H3 s28 (HR = 1.4; p < 0.005), and T-bet (HR = 1.4, p < 0.05) were found to be associated with inferior outcomes.
